Sanofi (SNY) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Sanofi  (NASDAQ: SNY)
 

Sanofi Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SNY Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) 5.49 % 7.99 % 8.08 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) - 1.44 % 1.81 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) 5.49 % 7.47 % 7.07 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) - 4.22 % 3.52 % 2.08 %
Revenue 5 Year Average Growth 4.57 % 7.41 % 8.65 % 10.59 %


SNY's Growth Comparisons in IV. Quarter 2025




Sanofi's Revenue slowed to the 5.49% year on year, improvement in the fourth quarter 2025 to 52.32 billions, underperforming the 7.99% growth in the Major Pharmaceutical Preparations industry and 8.08% Revenue growth in the Healthcare sector. Slow fourth quarter sales, in the Major Pharmaceutical Preparations industry and Healthcare sector, were portrayed in Sanofi results which underperformed overall market.

Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by 4.57% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2025 earnings reports, average yearly sales growth is 10.59%.

SNY Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Biopharma segment
-
-
Opella Business
-
-
Biopharma Dupixent
-
-
Biopharma Aubagio
-
-
Biopharma Industrial Sales
-
-
Biopharma Polio Pertussis Hib Vaccines
-
-
Biopharma Influenza Vaccines
-
-
Biopharma RSV Vaccines Beyfortus
-
-
Biopharma Meningitis Travel And Endemics Vaccines
-
-
Biopharma Nexviazyme
-
-
Biopharma Sarclisa
-
-
Biopharma ALTUVIIIO
-
-
Biopharma Rezurock
-
-
Biopharma Cablivi
-
-
Biopharma Xenpozyme
-
-
Biopharma Tzield
-
-
Europe
-
-
Europe Biopharma segment
-
-
Europe Biopharma Dupixent
-
-
Europe Biopharma Aubagio
-
-
Europe Biopharma Industrial Sales
-
-
Europe Biopharma Polio Pertussis Hib Vaccines
-
-
Europe Biopharma Influenza Vaccines
-
-
Europe Biopharma RSV Vaccines Beyfortus
-
-
Europe Biopharma Meningitis Travel And Endemics Vaccines
-
-
Europe Biopharma Nexviazyme
-
-
Europe Biopharma Sarclisa
-
-
Europe Biopharma Rezurock
-
-
Europe Biopharma Cablivi
-
-
Europe Biopharma Xenpozyme
-
-
Europe Biopharma Tzield
-
-
United States
-
-
United States Biopharma Dupixent
-
-
United States Biopharma Aubagio
-
-
United States Biopharma Industrial Sales
-
-
United States Biopharma Polio Pertussis Hib Vaccines
-
-
United States Biopharma Influenza Vaccines
-
-
United States Biopharma Pharmaceuticals Segment
-
-
United States Biopharma RSV Vaccines Beyfortus
-
-
United States Biopharma Meningitis Travel And Endemics Vaccines
-
-
United States Biopharma Nexviazyme
-
-
United States Biopharma Sarclisa
-
-
United States Biopharma ALTUVIIIO
-
-
United States Biopharma Rezurock
-
-
United States Biopharma Cablivi
-
-
United States Biopharma Xenpozyme
-
-
United States Biopharma Tzield
-
-
Other Countries In Results Biopharma Dupixent
-
-
Other Countries In Results Biopharma Aubagio
-
-
Other Countries In Results Biopharma Industrial Sales
-
-
Other Countries In Results Biopharma Polio Pertussis Hib Vaccines
-
-
Other Countries In Results Biopharma Influenza Vaccines
-
-
Other Countries In Results Biopharma Pharmaceuticals Segment
-
-
Other Countries In Results Biopharma RSV Vaccines Beyfortus
-
-
Other Countries In Results Biopharma Meningitis Travel And Endemics Vaccines
-
-
Other Countries In Results Biopharma Nexviazyme
-
-
Other Countries In Results Biopharma Sarclisa
-
-
Other Countries In Results Biopharma ALTUVIIIO
-
-
Other Countries In Results Biopharma Rezurock
-
-
Other Countries In Results Biopharma Cablivi
-
-
Other Countries In Results Biopharma Xenpozyme
-
-
Other Countries In Results Biopharma Tzield
-
-
Other
-
-
Reportable Geographical Zones
-
-
France
-
-
Other Countries
-
-
China
-
-
Total
-
-


Growth Rates of SNY's Income in the fourth quarter 2025


SNY Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) -12.52 % 53.67 % 27.58 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) - -27.23 % -17.75 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) -12.52 % 48.12 % 37.34 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) -12.52 % 13.45 % 9.73 % 6.96 %
Operating Income 5 Year Avg. Change -14.81 % 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) 39.75 % - - 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) 39.75 % -59.45 % -18.46 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) 39.75 % -10.62 % -5.94 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change -8.66 % -0.55 % 0.17 % -28.52 %

SNY Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) 39.75 % -26.27 % 16.74 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) - -43.67 % -34.36 % 11.12 %
Y / Y Net Income Change (Q4 TTM) 39.75 % 27.23 % 32.72 % 16.59 %
Sequential Net Income Change (Q4 TTM) 39.75 % 3.41 % 7.3 % 6.03 %
Net Income 5 Year Avg. Growth -8.66 % 14.55 % 9.21 % 22.96 %

SNY's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) - - - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth -8.37 % -10.79 % 0.17 % -28.52 %



SNY EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - -29.54 % 16.74 % -28.52 %
Q / Q EPS Net Growth (Q4 MRQ) - -32.72 % -34.36 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) - - - -99.87 %
EPS Net 5 Year Avg. Change -8.36 % 14.55 % 9.21 % 22.96 %



Sanofi reported bottom-line of $ 0.00 in the fourth quarter, compare to $ 2.48 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -29.54%, while Healthcare sector increased by 16.74%, and overall market improved by 21.56%.

Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by -8.36% on average in the last five years, while the S & P 500's including only the businesses with the fourth quarter 2025 financial results, average yearly income per share growth is 22.96%.

SNY Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) 9.44 % -15.04 % -10.43 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) - -44.24 % -28.87 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) 9.44 % 9.68 % 11.13 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) 9.44 % 1.75 % 1.97 % 2.41 %
Free Cash Flow 5 Year Avg. Change 7.61 % 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - - -88.83 % 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) - - -98.87 % -
Y / Y Net Cash Flow Change (Q4 TTM) - -21.47 % -23.28 % -
Sequential Net Cash Flow Change (Q4 TTM) - -44.27 % -25.17 % -
Net Cash Flow 5 Year Avg. Change -4.62 % 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) - 19.28 % 9.45 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) - 20.61 % 18.78 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) - 20.58 % 10.59 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) - 11.31 % 6.62 % 7.02 %
Capital Expenditures 5 Year Avg. Change - 7.84 % 8.61 % 14.74 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.